The US Food and Drug Administration (FDA) has approved GSK’s JIDEYTRO® (zidesamtinib) for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) whose disease has progressed following prior ROS1 tyrosine kinase inhibitor (TKI) therapy or platinum-based chemotherapy. The approval introduces a next-generation, highly selective ROS1 inhibitor designed to overcome resistance mechanisms associated with earlier-generation ROS1-targeted therapies while maintaining robust central nervous system (CNS) penetration.
The approval is supported by results from the ongoing Phase 1/2 ARROS-1 trial, a multicentre, open-label study evaluating zidesamtinib in patients with advanced ROS1-positive solid tumours. In patients previously treated with a ROS1 TKI, JIDEYTRO demonstrated clinically meaningful and durable objective responses, with sustained disease control across multiple resistance settings. The therapy also showed notable intracranial efficacy, producing responses in patients with measurable brain metastases, an important consideration given the high incidence of CNS progression in ROS1-positive NSCLC.
Among patients who had received prior chemotherapy but were ROS1 TKI-naïve, zidesamtinib also demonstrated high objective response rates and durable responses, supporting its broad activity across different treatment settings. The safety profile was generally manageable and consistent with targeted kinase inhibition. The most commonly reported adverse events included diarrhoea, nausea, constipation, fatigue, dizziness, peripheral oedema, and elevated liver enzymes. Dose modifications effectively managed most treatment-related toxicities, and no new safety concerns were identified.
ROS1 rearrangements occur in approximately 1–2% of patients with NSCLC, typically affecting younger individuals and never-smokers. Although currently available ROS1 inhibitors have significantly improved outcomes, acquired resistance and CNS disease remain major clinical challenges. Zidesamtinib was specifically developed to address these unmet needs through potent activity against ROS1 resistance mutations and enhanced penetration into the brain.
The FDA approval of JIDEYTRO provides an important new treatment option for patients with previously treated ROS1-positive NSCLC, particularly those whose disease has progressed on existing ROS1-targeted therapies. By extending disease control while effectively addressing intracranial disease, zidesamtinib represents a meaningful advancement in precision oncology and reinforces the continued evolution of targeted therapies for molecularly defined subsets of lung cancer.
